CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D000690: Amyotrophic Lateral Sclerosis NIH

(Synonyms: Amyotrophic Late, Amyotrophic Lateral, Amyotrophic Lateral S, Amyotrophic Lateral Scl, Amyotrophic Lateral Scle, Amyotrophic Lateral Sclero, Amyotrophic Lateral Sclerosi, Amyotrophic Lateral Sclerosis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug380 Baricitinib or Anakinra Wiki 1.00
drug611 Cannabis, Medical Wiki 1.00

Correlated MeSH Terms (23)


Name (Synonyms) Correlation
D000070627 Chronic Traumatic Encephalopathy NIH 1.00
D016472 Motor Neuron Disease NIH 1.00
D005879 Tourette Syndrome NIH 1.00
D012640 Seizures NIH 0.71
D000755 Anemia, Sickle Cell NIH 0.71
D001714 Bipolar Disorder NIH 0.71
D005356 Fibromyalgia NIH 0.58
D001927 Brain Diseases NIH 0.50
D010300 Parkinsonian NIH 0.50
D003424 Crohn Disease NIH 0.45
D000070642 Brain Injuries, Traumatic NIH 0.38
D015212 Inflammatory Bowel Diseases NIH 0.38
D059350 Chronic Pain NIH 0.35
D001930 Brain Injuries, NIH 0.33
D012598 Scoliosi NIH 0.30
D009103 Multiple Sclerosis NIH 0.29
D040921 Stress Disorders, Traumatic NIH 0.19
D014947 Wounds and Injuries NIH 0.19
D013313 Stress Disorders, Post-Traumatic NIH 0.18
D004194 Disease NIH 0.17
D013577 Syndrome NIH 0.10
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0006802 Abnormal anterior horn cell morphology HPO 1.00
HP:0007354 Amyotrophic lateral sclerosis HPO 1.00
HP:0100754 Mania HPO 0.71
HP:0001250 Seizure HPO 0.58
HP:0001298 Encephalopathy HPO 0.50
HP:0100280 Crohn's disease HPO 0.45
HP:0002037 Inflammation of the large intestine HPO 0.38
HP:0012532 Chronic pain HPO 0.35

There is one clinical trial.

Clinical Trials


1 Outcomes Mandate National Integration With Cannabis as Medicine

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

NCT03944447 Chronic Pain Chronic Pain Syndrome Chronic Pain Due to Injury Chronic Pain Due to Trauma Fibromyalgia Seizures Hepatitis C Cancer Crohn Disease HIV/AIDS Multiple Sclerosis Traumatic Brain Injury Sickle Cell Disease Post Traumatic Stress Disorder Tourette Syndrome Ulcerative Colitis Glaucoma Epilepsy Inflammatory Bowel Diseases Parkinson Disease Amyotrophic Lateral Sclerosis Chronic Traumatic Encephalopathy Anxiety Depression Insomnia Autism Opioid-use Disorder Bipolar Disorder Covid19 SARS-CoV Infection Drug: Cannabis, Medical
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic Wounds and Injuries
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years


HPO Nodes